Role of Nutrition in Inflammatory Bowel Disease (IBD): New Therapeutic Approaches and Recent Outcomes
DOI:
https://doi.org/10.6000/1929-5634.2012.01.02.4Keywords:
Inflammatory Bowel Disease, Nutrients, Fatty Acids and TreatmentAbstract
Inflammatory bowel disease (IBD) is the generic term given to a heterogeneous group of disorders of the gastrointestinal tract that are characterized by chronic inflammation. The major forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC), which are increasing in incidence, prevalence and severity in many countries; these are characterized by intestinal inflammation and are believed to involve complex interactions between genetic, immunological and environmental factors. The incidence continues to rise, both in low and in high-incidence areas. Several dietary regimes may modify disease symptoms, in part through their actions on the host microbe. However, other dietary factors could affect the microbiotic or genetic expression in IBD patients in different ways. The purpose of this review is to discuss the most recent evidence from the literature on the use of nutritional therapy in the treatment of IBD and to review the role of environmental factors on the progressive increase of prevalence. The epidemiological data reveal an increasing incidence of IBD in recent years, which may be the result of increased intake of simple sugars and consumption disproportionate of fat (saturated and unsaturated). Intestinal permeability and inflammation could improve with proper diet in protein, probiotics and FA (n-3 and n-6). Diet and the host microbiota are likely to play important but as yet poorly defined roles therefore, is necessary to continue investigating to implement molecular findings in clinical treatments or adjunctive therapies.
References
Podolsky DK. Inflammatory Bowel Disease. N Engl J Med 2002; 347: 417-29. http://dx.doi.org/10.1056/NEJMra020831 DOI: https://doi.org/10.1056/NEJMra020831
Yamamoto-Furusho JK. Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987-2006). J Clin Gastroenterol 2009; 43: 221-24. http://dx.doi.org/10.1097/MCG.0b013e31817a76b4 DOI: https://doi.org/10.1097/MCG.0b013e31817a76b4
Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 2010; 8: 564-77. http://dx.doi.org/10.1038/nrmicro2403 DOI: https://doi.org/10.1038/nrmicro2403
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-17. http://dx.doi.org/10.1038/nature10209 DOI: https://doi.org/10.1038/nature10209
Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med 2012; 1: 17-27. DOI: https://doi.org/10.1007/s11739-011-0673-9
Semrad CV. Use of Parenteral nutrition in patients with Inflammatory Bowel Disease. Gastroenterol Hepatol 2012; 8: 393-5.
Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D’Haens G, et al. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the world digestive health day 2010- Inflammatory Bowel Disease Task Force Meeting. Inflamm Bowel Dis 2011; 17: 639-44. http://dx.doi.org/10.1002/ibd.21409 DOI: https://doi.org/10.1002/ibd.21409
Loftus CG, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13: 254-61. http://dx.doi.org/10.1002/ibd.20029 DOI: https://doi.org/10.1002/ibd.20029
Lovasz BD, Golovics PA, Vegh Z, Lakatos PL. New trends in inflammatory bowel disease epidemiology and disease course in. Digest Liver Dis 2012: pii: S1590-8658(12)00328-3. doi: 10.1016/j.dld.2012.08.020. [Epub ahead of print]. http://dx.doi.org/10.1016/j.dld.2012.08.020 DOI: https://doi.org/10.1016/j.dld.2012.08.020
Kappelman MD, Moore KR, Allen JF, Cook SF. Recent trends in the prevalence of Crohn’s Disease and Ulcerative Colitis in a commercially insured US population. Dig Dis Sci 2012; doi: 10.1007/s10620-012-2371-5 [Epub ahead of print]. http://dx.doi.org/10.1007/s10620-012-2371-5 DOI: https://doi.org/10.1007/s10620-012-2371-5
Song OW, Wang Y, Chung CE, Song Bonita, Lee W. Is obesity development associated with dietary sugar intake in the U.S.? Nutrition 2012; 1-5.
Jakobsen C, Paerregaard A, Munkholm P, Wewer V. Environmental factors and risk of developing paediatric inflammatory bowel disease - A population based study 2007-2009. J Crohns Colitis 2012; [Epub ahead of print]. http://dx.doi.org/10.1016/j.crohns.2012.05.024 DOI: https://doi.org/10.1016/j.crohns.2012.05.024
Knoch B, Barnett MP, Zhu S, Park ZA, Nones K, Dommels YE, et al. Genomewide analysis of dietary eicosapentaenoic acid and oleic acidinduced modulation of colon inflammation in interleukin-10 gene-deficient mice. J Nutrigenet Nutrigenomics 2009; 2: 9-28. http://dx.doi.org/10.1159/000134292 DOI: https://doi.org/10.1159/000134292
Molnár K, Vannay A, Szebeni B, Bánki NF, Sziksz E, Cseh A, et al. Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease. World J Gastroenterol 2012; 18: 3254-9.
Schicho R, Shaykhutdinov R, Ngo J, Nazyrova A, Schneider C, et al. Panaccione R. Quantitative metabolomic profiling of serum, plasma, and urine by 1H NMR spectroscopy discriminates between patients with Inflammatory Bowel Disease and healthy individuals. J Proteome Res 2012; 11: 3344−57. http://dx.doi.org/10.1021/pr300139q DOI: https://doi.org/10.1021/pr300139q
Koleva PT, Valcheva RS, Sun X, Gänzle MG, Dieleman LA. Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr 2012; 16: 1-11. DOI: https://doi.org/10.1017/S0007114511007203
Guarner F. Prebiotics in inflammatory bowel diseases. Br J Nutr 2007; 1: S85-9. DOI: https://doi.org/10.1017/S0007114507832958
Walkera AW, Lawleyb TD. Therapeutic modulation of intestinal dysbiosis, Pharmacol Res 2012; pii: S1043-6618(12)00183-1. doi: 10.1016/j.phrs.2012.09.008. [Epub ahead of print]. http://dx.doi.org/10.1016/j.phrs.2012.09.008 DOI: https://doi.org/10.1016/j.phrs.2012.09.008
Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-80. http://dx.doi.org/10.1038/nature09944 DOI: https://doi.org/10.1038/nature09944
Jonkers D, Penders J, Masclee A, Pierik M, et al. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-23. http://dx.doi.org/10.2165/11632710-000000000-00000 DOI: https://doi.org/10.2165/11632710-000000000-00000
Mañé J, Lorén V, Pedrosa E, Ojanguren I, Xaus J, Cabré E et al. Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice. Inflamm Bowel Dis 2009; 15: 1155-63. http://dx.doi.org/10.1002/ibd.20908 DOI: https://doi.org/10.1002/ibd.20908
Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, et al. Kopecny J. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS ONE 2011; 6(11): e27961. http://dx.doi.org/10.1371/journal.pone.0027961 DOI: https://doi.org/10.1371/journal.pone.0027961
Xue H, Sufit AJD, Wischmeyer PE. Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. J Parenter Enteral Nutr 2011; 35: 188-97. http://dx.doi.org/10.1177/0148607110381407 DOI: https://doi.org/10.1177/0148607110381407
Benjamin J, Makharia G, Ahuja V, Anand KD, Kalaivani M, Datta S, et al. Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn’s Disease: a randomized controlled trial. Dig Dis Sci 2012; 57: 1000-12. http://dx.doi.org/10.1007/s10620-011-1947-9 DOI: https://doi.org/10.1007/s10620-011-1947-9
Cabré E, Domènech E. Impact of environmental and dietary factors on the course of inflammatory bowel disease. World J Gastroenterol 2012; 18: 3814-22. http://dx.doi.org/10.3748/wjg.v18.i29.3814 DOI: https://doi.org/10.3748/wjg.v18.i29.3814
Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn‘s disease. Cochrane Database Syst Rev 2007; 24(1): CD000542. DOI: https://doi.org/10.1002/14651858.CD000542.pub2
Williams HRT, Willsmore JD, Cox J, Walker DG, Cobbold JFL, Taylor-Robinson SD, Orchard TR. Serum metabolic profiling in Inflammatory Bowel Disease. Dig Dis Sci 2012; 57: 2157-65. http://dx.doi.org/10.1007/s10620-012-2127-2 DOI: https://doi.org/10.1007/s10620-012-2127-2
Sánchez-Fidalgo S, Villegas I, Cárdeno A, Talero E, Sánchez-Hidalgo M, Motilva V et al. Extra-virgin olive oil-enriched diet modulates DSS-colitis-associated colon carcinogenesis in mice. Clin Nutr 2010; 29: 663-73. http://dx.doi.org/10.1016/j.clnu.2010.03.003 DOI: https://doi.org/10.1016/j.clnu.2010.03.003
Borniquela S, Janssona EA, Coleb MP, Freemanb BA, Lundberga JO. Nitrated oleic acid up-regulates PPARγ and attenuates experimental inflammatory bowel disease. Free Radic Biol Med 2010; 48: 499-505. http://dx.doi.org/10.1016/j.freeradbiomed.2009.11.014 DOI: https://doi.org/10.1016/j.freeradbiomed.2009.11.014
Wisely BG, Miller BA, Davis GR, Thornquest DA, Johonson R, Spitzer T, et al. Hepatocyte nuclear factor 4 is a transcription factor the constitutively binds fatty acids. Structure 2002; 10: 1225-34. http://dx.doi.org/10.1016/S0969-2126(02)00829-8 DOI: https://doi.org/10.1016/S0969-2126(02)00829-8
Bueno-Hernández N, Sánchez-Muñoz F, Barreto-Zuñiga R, Dominguez-López A, Yamamoto-Furusho JK. Expression of HNF4g is downregulated in patients with active Ulcerative Colitis (UC) compared to UC patients in remission and healthy controls. Inflamm Bowel Dis 2011; 8: E91. http://dx.doi.org/10.1002/ibd.21753 DOI: https://doi.org/10.1002/ibd.21753
Kaser A, Zeissig S, Blumberg RS. Inflammatory Bowel Disease. Annu Rev Immunol 2010; 28: 573-621. http://dx.doi.org/10.1146/annurev-immunol-030409-101225 DOI: https://doi.org/10.1146/annurev-immunol-030409-101225
Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc 2002; 61: 345-58. http://dx.doi.org/10.1079/PNS2002166 DOI: https://doi.org/10.1079/PNS2002166
Ramakers JD, Mensink RP, Schaart G, Plat J. Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. Lipids 2007; 42: 687-98. http://dx.doi.org/10.1007/s11745-007-3071-3 DOI: https://doi.org/10.1007/s11745-007-3071-3
Cooney JM, Barnett MPG, Brewster D, Knoch B, McNabb WC, Laing WA, Roy NC. Proteomic analysis of colon tissue from Interleukin-10 gene-deficient mice fed polyunsaturated fatty acids with comparison to transcriptomic analysis. J Proteome Res 2012; 11: 1065-77. http://dx.doi.org/10.1021/pr200807p DOI: https://doi.org/10.1021/pr200807p
Mañé J, Pedrosa E, Lorén V, Ojanguren I, Fluvia L, Cabré E, et al. Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in Interleukin-10-deficient Mice. J Nutr 2009; 139: 603-10. http://dx.doi.org/10.3945/jn.108.101170 DOI: https://doi.org/10.3945/jn.108.101170
Mbodjia K, Charpentiera C, Guérina C, Quereca C, Bole-Feysota C, Azizc M. Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-κB in rats with TNBS-induced colitis. J Nutr Biochem 2012; [Epub ahead of print]. DOI: https://doi.org/10.1016/j.jnutbio.2012.03.022
James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71: 343S-8S. DOI: https://doi.org/10.1093/ajcn/71.1.343S
Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006; 103; 11276-81. http://dx.doi.org/10.1073/pnas.0601280103 DOI: https://doi.org/10.1073/pnas.0601280103
Downloads
Published
How to Cite
Issue
Section
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
